Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Aardvark Therapeutics, Inc. (AARD) Encourages Shareholders To Inquire About Securities Fraud Class Action
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) securities between February 10, 2025 and May 14, 2026, inclusive (the “Class Period”). Aardvark investors have until October 13, 2026 to file a lead plaintiff motion.
IF YOU SUFFERED A LOSS ON YOUR AARDVARK THERAPEUTICS, INC. (AARD) INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS
What Happened?
On February 27, 2026, Aardvark issued a press release “announc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial” due to a “reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study” and said that it is “conducting a comprehensive review of the data to inform next steps.”
